Table 1 Baseline demographics and clinical characteristics
From: Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions
|  | DREAM (N = 616) | MENSA (N = 576) | SIRIUS (N = 135) | MUSCA (N = 551) | Total (N = 1878) |
|---|---|---|---|---|---|
Age, years, mean (SD) | 48.6 (11.3) | 50.1 (14.3) | 49.9 (12.3) | 50.9 (13.5) | 49.8 (13.0) |
Female, n (%) | 387 (63) | 329 (57) | 74 (55) | 325 (59) | 1115 (59) |
BMI, kg/m2, mean (SD) | 28.5 (5.95) | 27.8 (5.83) | 28.7 (6.01) | 28.2 (6.40) | 28.2 (6.06) |
Duration of asthma, years, mean (SD) | 19.1 (14.3) | 19.9 (13.8) | 18.7 (13.1) | 19.5 (14.8) | 19.5 (14.2) |
Number of exacerbations in the previous year, n (%) |  |  |  |  |  |
  ≤ 2 | 286 (46) | 246 (43) | 67 (50) | 357 (65) | 956 (51) |
 3 | 154 (25) | 141 (24) | 20 (15) | 96 (17) | 411 (22) |
  ≥ 4 | 176 (29) | 189 (33) | 48 (36) | 98 (18) | 511 (27) |
Receiving maintenance OCS therapy at baseline, n (%) | 188 (31) | 144 (25) | 135 (100) | 131 (24) | 598 (32) |
% predicted pre-bronchodilator FEV1, mean (SD) | 59.7 (15.89) | 61.0 (17.99) | 58.7 (17.75) | 58.6 (16.04) | 59.7 (16.75) |
Blood eosinophil count, cells/µL, geometric mean (SD logs) | 260 (0.957) | 300 (0.950) | 250 (1.081) | 340 (0.943) | 290 (0.966) |